SG169381A1 - New citrate salt of an indole derivative and its pharmaceutical use - Google Patents

New citrate salt of an indole derivative and its pharmaceutical use

Info

Publication number
SG169381A1
SG169381A1 SG201100793-7A SG2011007937A SG169381A1 SG 169381 A1 SG169381 A1 SG 169381A1 SG 2011007937 A SG2011007937 A SG 2011007937A SG 169381 A1 SG169381 A1 SG 169381A1
Authority
SG
Singapore
Prior art keywords
pharmaceutical use
citrate salt
indole derivative
salt
new
Prior art date
Application number
SG201100793-7A
Other languages
English (en)
Inventor
Anna-Lena Berg
Ratan Bhat
Tesfai Sebhatu
Erica Staahle
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of SG169381A1 publication Critical patent/SG169381A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
SG201100793-7A 2006-02-02 2007-01-31 New citrate salt of an indole derivative and its pharmaceutical use SG169381A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US76455106P 2006-02-02 2006-02-02

Publications (1)

Publication Number Publication Date
SG169381A1 true SG169381A1 (en) 2011-03-30

Family

ID=38327680

Family Applications (1)

Application Number Title Priority Date Filing Date
SG201100793-7A SG169381A1 (en) 2006-02-02 2007-01-31 New citrate salt of an indole derivative and its pharmaceutical use

Country Status (24)

Country Link
US (2) US8008294B2 (ko)
EP (1) EP1981869A4 (ko)
JP (1) JP2009525324A (ko)
KR (1) KR20080098022A (ko)
CN (2) CN101378754A (ko)
AR (1) AR059225A1 (ko)
AU (1) AU2007210336B2 (ko)
BR (1) BRPI0706745A2 (ko)
CA (1) CA2641900A1 (ko)
EC (1) ECSP088647A (ko)
IL (1) IL192888A0 (ko)
MX (1) MX2008009719A (ko)
MY (1) MY146102A (ko)
NO (1) NO20083784L (ko)
NZ (1) NZ570849A (ko)
PE (1) PE20090192A1 (ko)
RU (1) RU2415137C2 (ko)
SA (1) SA07280004B1 (ko)
SG (1) SG169381A1 (ko)
TW (1) TW200800977A (ko)
UA (1) UA94251C2 (ko)
UY (1) UY30126A1 (ko)
WO (1) WO2007089191A1 (ko)
ZA (1) ZA200806725B (ko)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SA07280004B1 (ar) * 2006-02-02 2011-10-29 استرازينيكا ايه بي ملح سترات من مركب 2- هيدروكسي –3- [5- (مورفولين –4- يل ميثيل) بيريدين –2- يل] 1h- إندول –5- كربونيتريل سترات
CN101679353A (zh) * 2007-04-18 2010-03-24 阿斯利康(瑞典)有限公司 制备化合物2-羟基-3-[5-(吗啉-4-基甲基)吡啶-2-基]1h-吲哚-5-腈701的新方法
WO2009017452A1 (en) * 2007-07-30 2009-02-05 Astrazeneca Ab New crystalline forms of 2 -hydroxy- 3- [5- (morpholin- 4- ylmethyl) pyridin-2-yl] ih- indole- 5 -carbonitrile citrate
US20100189788A1 (en) 2009-01-23 2010-07-29 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline base formulation
AU2020218366A1 (en) 2019-02-08 2021-09-16 Frequency Therapeutics, Inc. Valproic acid compounds and Wnt agonists for treating ear disorders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2231685T3 (es) 2001-04-05 2005-05-16 Torrent Pharmaceuticals Ltd Compuestos heterociclicos para complicaciones vasculares diabeticas y relacionadas con la edad.
JP2003009588A (ja) 2001-06-20 2003-01-10 Toshiba Corp 車両連続運転装置用インバータ装置
SE0200979D0 (sv) * 2002-03-28 2002-03-28 Astrazeneca Ab New compounds
SE0302546D0 (sv) * 2003-09-24 2003-09-24 Astrazeneca Ab New compounds
MXPA05013637A (es) * 2003-08-13 2006-02-24 Chiron Corp Inhibidores gsk-3 y usos de los mismos.
EP2395000A1 (en) 2004-12-30 2011-12-14 Astex Therapeutics Limited Benzimidazole compounds that modulate the activity of CDK, GSK and aurora kinases
SA07280004B1 (ar) * 2006-02-02 2011-10-29 استرازينيكا ايه بي ملح سترات من مركب 2- هيدروكسي –3- [5- (مورفولين –4- يل ميثيل) بيريدين –2- يل] 1h- إندول –5- كربونيتريل سترات

Also Published As

Publication number Publication date
EP1981869A4 (en) 2010-08-25
CN101378754A (zh) 2009-03-04
EP1981869A1 (en) 2008-10-22
ZA200806725B (en) 2009-07-29
AU2007210336A1 (en) 2007-08-09
CN101379053A (zh) 2009-03-04
IL192888A0 (en) 2009-02-11
US20070203137A1 (en) 2007-08-30
UA94251C2 (ru) 2011-04-26
AR059225A1 (es) 2008-03-19
NO20083784L (no) 2008-10-13
RU2415137C2 (ru) 2011-03-27
MX2008009719A (es) 2008-09-04
WO2007089191A1 (en) 2007-08-09
CA2641900A1 (en) 2007-08-09
JP2009525324A (ja) 2009-07-09
US20090023732A1 (en) 2009-01-22
US8008294B2 (en) 2011-08-30
UY30126A1 (es) 2007-09-28
SA07280004B1 (ar) 2011-10-29
MY146102A (en) 2012-06-29
ECSP088647A (es) 2008-08-29
RU2008131906A (ru) 2010-03-10
NZ570849A (en) 2011-01-28
KR20080098022A (ko) 2008-11-06
BRPI0706745A2 (pt) 2011-04-05
TW200800977A (en) 2008-01-01
PE20090192A1 (es) 2009-03-20
AU2007210336B2 (en) 2011-03-24

Similar Documents

Publication Publication Date Title
UA99141C2 (ru) Замещенные производные индазола, активные в качестве ингибиторов киназы
EA200970595A1 (ru) Производные замещенных индазолов, активные в качестве ингибиторов киназ
CY1117667T1 (el) 3,4-διαρυλπυραζολια ως αναστολεις κινασης πρωτεϊνης
HK1136292A1 (en) Substituted pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
WO2009071480A3 (en) Substituted dihydropteridin-6-one derivatives, process for their preparation and their use as kinase inhibitors
WO2008040534A3 (en) Non-mucoadhesive film dosage forms
NO20083863L (no) Pyrazoler som 11-beta-hsd-1
AU2008347158A8 (en) Oral pharmaceutical dosage forms
MY147994A (en) Azabiphenylaminobenzoic acid derivatives as dhodh inhibitors
MX2010010647A (es) Proceso para preparar formulaciones de dabigatran para administracion oral.
WO2008002245A3 (en) Imidazol-pyrimidine derivatives for treatment of diseases related to glycogen synthase kinase (gsk3)
MX2020008616A (es) Rocio de fentanilo sublingual.
IS8132A (is) Pýrósóló-kínasólín afleiður, aðferð við framleiðslu þeirra og notkun sem kínasa hindrar
ATE470443T1 (de) Indol-1-yl-essigsäurederivate
WO2005005414A3 (en) Pyrazolyl-indole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
WO2008002244A3 (en) Imidazol-pyrimidine derivatives for treatment of diseases related to glycogen synthase kinase (gsk3)
TW200700062A (en) Pharmaceutical compositions
NO20081942L (no) Karbamoylbenzotriazolderivater som inhibitorer av lipaser og fosfolipaser
BR112014009910A2 (pt) formulações de sal de meglumina de ácido 1-(5,6-dicloro-1h-benzo[d]imidazol-2-il)-1h-pirazol-4-carboxílico
WO2011037976A3 (en) Pramipexole pharmaceutical formulations
MY146102A (en) New citrate salt of an indole derivative and its pharmaceutical use
UA102219C2 (ru) Замещенные пиразолохиназолиновые производные, способ их получения и их применения как ингибиторов киназы
WO2010044097A3 (en) Novel dosage form of paliperidone and process for preparing the same
WO2008051527A3 (en) Sustained release of agents for localized pain management
HK1120417A1 (en) Stable nanoparticle formulations